Eric van Hooren | Chief Development Officer
Eric van Hooren has over 20 years of experience in the pharmaceutical industry. He has a broad background in strategic drug development for both new biological and new chemical entities, as well as in global clinical trial management and medical marketing.
Prior to joining Xenikos, Eric was Director Clinical Operations at Acerta-Pharma, where he was responsible for the set up and line management of the European clinical operations group, including the execution of Phase 1, 2 and 3 clinical trial programs with the compound acalabrutinib, a potential best-in-class irreversible oral Bruton's tyrosine kinase (BTK) inhibitor, that contributed to a major transaction with AstraZeneca in December 2015. Eric previously worked as a Program Manager at Merck, where he managed Women’s Health Programs. He also worked for many years at Organon in positions of increasing responsibility in both clinical development and medical marketing.
At Xenikos, Eric will be responsible for preparing and executing the EU/US randomized active-controlled Phase 3 pivotal study of T-Guard in acute graft-versus-host disease (GVHD), as well as exploring new potential indications that might benefit from T-Guard’s promise as a therapeutic tool for safely and swiftly resetting the body’s immune system in T-cell-mediated diseases.